Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease - 18/03/26
, Yukinori Sakata b , Kinuyo Koizumi b , Akira Endo b , Weijie Kuang b , Kenta Sumitomo b , Mika Ishii b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Lecanemab is a monoclonal antibody targeting amyloid-beta protofibrils, indicated for patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease.
Objectives |
This study reports interim findings of an ongoing, multicenter, prospective, observational post-marketing study for all patients treated with lecanemab in routine clinical practice in Japan, focusing on amyloid-related imaging abnormalities (ARIAs) and infusion-related reactions primarily observed during up to 28 weeks after treatment initiation.
Methods |
Patients treated with lecanemab at any medical institutions across Japan are included in the study. Data are collected using an electronic data capture system via standardized case report forms (CRFs). Study items included the incidence of ARIA, ARIA-edema or effusion (-E), ARIA-hemorrhage (-H: cerebral microhemorrhages, superficial siderosis, and macrohemorrhage), and infusion-related reactions, reported as adverse drug reactions.
Results |
As of July 5, 2025, CRFs from 2675 patients were collected, of whom 2672 had data available for the interim analysis. The median age was 76.0 years, and 62.6 % (1672/2672) of patients were diagnosed with MCI. At Week 28, 7.3 % (195/2672) of patients discontinued treatment, with a mean treatment duration of 189.6 ± 34.4 days. Among 2634 patients confirmed to have undergone MRI scans after treatment initiation, ARIA was observed in 7.1 % (188/2634) of patients, ARIA-E in 3.0 % (78/2634), and ARIA-H in 5.2 % (137/2634). Serious ARIA-H (macrohemorrhage) occurred in two patients (0.1 %). Infusion-related reactions were observed in 17.0 % (455/2672), including 0.7 % (18/2672) serious cases. The proportion of patients who experienced ARIA was highest in patients with apolipoprotein E ( APOE ) ε4 homozygotes.
Conclusion |
This interim analysis represents one of the largest real-world lecanemab cohorts reported globally to date. Although absolute rates are not directly comparable with those from clinical trials, the trends in ARIA distributions across APOE genotypes and infusion-related reactions were comparable to those observed in clinical trials.
Le texte complet de cet article est disponible en PDF.Keywords : Lecanemab, Amyloid-related imaging abnormalities, Infusion-related reactions, Post-marketing study
Plan
Vol 13 - N° 5
Article 100541- mai 2026 Retour au numéro
Article précédent
- Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake
- Arnaud Charil, Todd M. Nelson, Anthonin Reilhac, Viswanath Devanarayan, Shobha Dhadda, Michael C. Irizarry, Lynn D. Kramer, Larisa Reyderman
- Characteristics of infusion-related reactions to lecanemab in early Alzheimer’s disease: A multicenter real-world study in Northwestern China
- Peijie Liu, Jie Liu, Jin Wang, Ying Du, Zhirong Liu, Hong Zhang, Aiqin Zhu, Gejuan Zhang, Xinling Meng, Chunmei Zhao, Weiping Zhang, Liangjun Dang, Wei Zhang, Qiumin Qu, Yan Qu
Bienvenue sur EM-consulte, la référence des professionnels de santé.